HCPCS Codes Similar to G9839

HCPCS Codes Similar to “G9839” Code.
Anti-egfr monoclonal antibody therapy

G9844 Patient did not receive anti-egfr monoclonal antibody therapy Code added date: 20170101 Code effective date: 20170101 TXT \| PDF \| XML \| JSON	G9845 Patient received anti-egfr monoclonal antibody therapy Code added date: 20170101 Code effective date: 20170101 TXT \| PDF \| XML \| JSON
M0235 Intravenous infusion, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, not otherwise classified, first dose Code added date: 20251001 Code effective date: 20251001 TXT \| PDF \| XML \| JSON	M0236 Intravenous infusion, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, includes infusion and post administration monitoring, not otherwise classified, second dose Code added date: 20251001 Code effective date: 20251001 TXT \| PDF \| XML \| JSON
Q0235 Injection, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, not otherwise classified, 1 mg Code added date: 20251001 Code effective date: 20251001 TXT \| PDF \| XML \| JSON	S9562 Home injectable therapy, palivizumab or other monoclonal antibody for rsv, including administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem Code added date: 20030101 Code effective date: 20230401 TXT \| PDF \| XML \| JSON
G9840 Ras (kras and nras) gene mutation testing performed before initiation of anti-egfr moab Code added date: 20170101 Code effective date: 20180101 TXT \| PDF \| XML \| JSON	G9841 Ras (kras and nras) gene mutation testing not performed before initiation of anti-egfr moab Code added date: 20170101 Code effective date: 20180101 TXT \| PDF \| XML \| JSON
M1412 Patients with metastatic nsclc with epidermal growth factor receptor (egfr) mutations, alk genomic tumor aberrations, or other targetable genomic abnormalities with approved first-line targeted therapy, such as nsclc with ros1 rearrangement, braf v600e mutation, ntrk 1/2/3 gene fusion, met ex14 skipping mutation, and ret rearrangement Code added date: 20250101 Code effective date: 20250101 TXT \| PDF \| XML \| JSON	G8868 Patients receiving a first course of anti-tnf therapy Code added date: 20120101 Code effective date: 20170101 TXT \| PDF \| XML \| JSON
G8869 Patient has documented immunity to hepatitis b and initiating anti-tnf therapy Code added date: 20120101 Code effective date: 20180101 TXT \| PDF \| XML \| JSON	G8870 Hepatitis b vaccine injection administered or previously received and is receiving a first course of anti-tnf therapy Code added date: 20120101 Code effective date: 20160101 TXT \| PDF \| XML \| JSON
G8871 Patient not receiving a first course of anti-tnf therapy Code added date: 20120101 Code effective date: 20160101 TXT \| PDF \| XML \| JSON	G9132 Oncology; disease status; prostate cancer, limited to adenocarcinoma; hormone-refractory/androgen-independent (e.g., rising psa on anti-androgen therapy or post-orchiectomy); clinical metastases (for use in a medicare-approved demonstration project) Code added date: 20070101 Code effective date: 20070101 TXT \| PDF \| XML \| JSON